Literature DB >> 18583168

High prevalence of SURF1 c.845_846delCT mutation in Polish Leigh patients.

Dorota Piekutowska-Abramczuk1, Ewa Popowska, Maciej Pronicki, Elzbieta Karczmarewicz, Dorota Tylek-Lemanska, Jolanta Sykut-Cegielska, Tamara Szymanska-Dembinska, Liliana Bielecka, Malgorzata Krajewska-Walasek, Ewa Pronicka.   

Abstract

Leigh syndrome is a neuropathological disorder with typical morphological changes in brain, appearing regardless of diverse molecular background. One of the most common enzymatic defects in Leigh patients is cytochrome c oxidase deficiency associated with recessive mutations in the SURF1 gene. To assess the SURF1 mutation profile among Polish patients we studied 41 affected children from 34 unrelated families by PCR-SSCP and sequencing. Four novel mutations, c.39delG, c.752-1G>C, c.800_801insT, c.821A>G, and five described pathogenic changes, c.311_312insAT312_321del10, c.688C>T, c.704T>C, c.756_757delCA, c.845_846delCT, were identified in 85.3% of analysed probands. One mutation, c.845_846delCT, was identified in 77.6% of SURF1 alleles. Up to now, it has been reported only in 9% of alleles in other parts of the world. The deletion was used as LS(SURF1-) marker in population studies. Eight heterozygous carriers of the mutation were found in a cohort of 2890 samples. The estimated c.845_846delCT allele frequency is 1:357 (0.28+/-0.2%), and the lowest predicted LS(SURF1-) frequency in Poland 1:126,736.births. Relatively high frequency of LS(SURF1-) in Poland with remarkable c.845_846delCT mutation dominance allows one to start the differential diagnosis of LS in each patient of Polish (and probably Slavonic) origin from the direct search for c.845_846delCT SURF1 mutation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18583168     DOI: 10.1016/j.ejpn.2008.03.009

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  5 in total

Review 1.  Regulation of mitochondrial respiratory chain biogenesis by estrogens/estrogen receptors and physiological, pathological and pharmacological implications.

Authors:  Jin-Qiang Chen; Patrick R Cammarata; Christopher P Baines; James D Yager
Journal:  Biochim Biophys Acta       Date:  2009-06-23

2.  Delineation of molecular findings by whole-exome sequencing for suspected cases of paediatric-onset mitochondrial diseases in the Southern Chinese population.

Authors:  Mandy H Y Tsang; Anna K Y Kwong; Kate L S Chan; Jasmine L F Fung; Mullin H C Yu; Christopher C Y Mak; Kit-San Yeung; Richard J T Rodenburg; Jan A M Smeitink; Rachel Chan; Thomas Tsoi; Joannie Hui; Shelia S N Wong; Shuk-Mui Tai; Victor C M Chan; Che-Kwan Ma; Sharon T H Fung; Shun-Ping Wu; W K Chak; Brian H Y Chung; Cheuk-Wing Fung
Journal:  Hum Genomics       Date:  2020-09-10       Impact factor: 4.639

3.  Tissue- and species-specific differences in cytochrome c oxidase assembly induced by SURF1 defects.

Authors:  Nikola Kovářová; Petr Pecina; Hana Nůsková; Marek Vrbacký; Massimo Zeviani; Tomáš Mráček; Carlo Viscomi; Josef Houštěk
Journal:  Biochim Biophys Acta       Date:  2016-01-13

4.  Difficulties in recognition of pyruvate dehydrogenase complex deficiency on the basis of clinical and biochemical features. The role of next-generation sequencing.

Authors:  E Ciara; D Rokicki; P Halat; A Karkucińska-Więckowska; D Piekutowska-Abramczuk; J Mayr; J Trubicka; T Szymańska-Dębińska; M Pronicki; M Pajdowska; M Dudzińska; M Giżewska; M Krajewska-Walasek; J Książyk; W Sperl; R Płoski; E Pronicka
Journal:  Mol Genet Metab Rep       Date:  2016-04-18

5.  New perspective in diagnostics of mitochondrial disorders: two years' experience with whole-exome sequencing at a national paediatric centre.

Authors:  Ewa Pronicka; Dorota Piekutowska-Abramczuk; Elżbieta Ciara; Joanna Trubicka; Dariusz Rokicki; Agnieszka Karkucińska-Więckowska; Magdalena Pajdowska; Elżbieta Jurkiewicz; Paulina Halat; Joanna Kosińska; Agnieszka Pollak; Małgorzata Rydzanicz; Piotr Stawinski; Maciej Pronicki; Małgorzata Krajewska-Walasek; Rafał Płoski
Journal:  J Transl Med       Date:  2016-06-12       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.